Read More Pharma Industry News Can KST-6051 unlock broader KRAS cancer treatment beyond G12C inhibitors KST-6051 enters Phase 1 with AbbVie Inc. backing. Discover how pan-KRAS inhibitors could expand treatment across KRAS-driven cancers. bySoujanya RaviMay 1, 2026